» Articles » PMID: 22649708

Inhibition of DNA Gyrase by Levofloxacin and Related Fluorine-containing Heterocyclic Compounds

Overview
Journal Acta Naturae
Specialty Biology
Date 2012 Jun 1
PMID 22649708
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Fluoroquinolones are an important class of modern and efficient antibacterial drugs with a broad spectrum of activity. Levofloxacin (the optically active form of ofloxacin) is one of the most promising fluoroquinolone drugs, and its antibacterial activity is substantially higher than the activity of other drugs of the fluoroquinolone family. Earlier, in the Postovsky Institute of Organic Synthesis, UB RAS, an original method of levofloxacin synthesis was developed, and now the pilot batch of the drug is being prepared. Bacterial DNA gyrase is a specific target of fluoroquinolones; hence, the study of the enzyme-drug interaction is of theoretical and practical importance. Moreover, the parameters of DNA gyrase inhibition may serve as a criterion for drug quality. Here, we present the results of studying the interaction of DNA gyrase with a number of fluoroquinolones and their analogs: intermediates and semi-products of the levofloxacin synthesis, and also samples from the pilot batches of this drug. The importance of two structural elements of the levofloxacin molecule for the efficiency of the inhibition is revealed. The data obtained may be useful for the design of new drugs derived from levofloxacin.

Citing Articles

Levofloxacin reposition-based design: synthesis, biological evaluation of new levofloxacin derivatives targeting topoisomerase II beta polymerase as promising anticancer agents, molecular docking, and physicochemical characterization.

Mahmoud Z, Ismail M, Kamel M, Youssef A RSC Adv. 2024; 14(38):28098-28119.

PMID: 39228758 PMC: 11369887. DOI: 10.1039/d4ra03975k.


Antimicrobial Action Mechanisms of Natural Compounds Isolated from Endophytic Microorganisms.

Eshboev F, Mamadalieva N, Nazarov P, Hussain H, Katanaev V, Egamberdieva D Antibiotics (Basel). 2024; 13(3).

PMID: 38534706 PMC: 10967585. DOI: 10.3390/antibiotics13030271.


Current and Emerging Inhaled Antibiotics for Chronic Pulmonary and Infections in Cystic Fibrosis.

Li D, Schneider-Futschik E Antibiotics (Basel). 2023; 12(3).

PMID: 36978351 PMC: 10044129. DOI: 10.3390/antibiotics12030484.


Acyldepsipeptide Analogues: A Future Generation Antibiotics for Tuberculosis Treatment.

Cobongela S, Makatini M, Mdluli P, Sibuyi N Pharmaceutics. 2022; 14(9).

PMID: 36145704 PMC: 9502522. DOI: 10.3390/pharmaceutics14091956.


Mechanism-Based Approach to New Antibiotic Producers Screening among Actinomycetes in the Course of the Citizen Science Project.

Volynkina I, Zakalyukina Y, Alferova V, Belik A, Yagoda D, Nikandrova A Antibiotics (Basel). 2022; 11(9).

PMID: 36139977 PMC: 9495171. DOI: 10.3390/antibiotics11091198.


References
1.
Hayakawa I, Atarashi S, Yokohama S, Imamura M, Sakano K, Furukawa M . Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother. 1986; 29(1):163-4. PMC: 180386. DOI: 10.1128/AAC.29.1.163. View